Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin

This publication has 25 references indexed in Scilit:

• Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir
  Clinical Pharmacokinetics, 2013
• Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
• Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir
  Antimicrobial Agents and Chemotherapy, 2012
• Integration of Antiretroviral Therapy with Tuberculosis Treatment
  New England Journal of Medicine, 2011
• Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
  AIDS, 2011
• Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers
  Antimicrobial Agents and Chemotherapy, 2010
• Antiretroviral Drug-Resistant Mutations at Baseline and at Time of Failure of Antiretroviral Therapy in HIV Type 1-Coinfected TB Patients
  AIDS Research and Human Retroviruses, 2009
• Better Adherence with Once‐Daily Antiretroviral Regimens: A Meta‐Analysis
  Clinical Infectious Diseases, 2009
• Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver
  Biochemical Pharmacology, 2005
• Pharmacokinetic Interactions with Rifampicin
  Clinical Pharmacokinetics, 2003